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Precursor B-cell lymphoblastic lymphoma (B-LBL) is an uncommon high-grade neoplasm 
of immature B cells. It occurs predominantly in childhood with extranodal involvement 
such as skin and bone. Therefore, primary cutaneous involvement in elderly adults is a 
very rare manifestation of B-LBL. Here, we report a 78-year-old man with B-LBL presenting 
as a single cutaneous lesion which was immunohistochemically positive for leukocyte 
common antigen (LCA), CD79a, paired box 5 (PAX5), B cell lymphoma-2 (bcl-2), and ter-
minal deoxynucleotidyl transferase (TdT) staining, but was without systemic involve-
ment. The patient was treated using cyclophosphamide, adriamycin, vincristine, and pre-
dnisolone (CHOP), and achieved complete response (CR) at the first response assess-
ment conducted after 3 CHOP cycles. After an additional cycle of CHOP treatment, radio-
therapy was administered at a total dose of 3,600 cGy over 4 weeks. At the 21-month 
follow-up, he had maintained CR.
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INTRODUCTION
Lymphoblastic lymphoma (LBL) is a highly aggressive sub-
type of non-Hodgkin’s lymphoma (NHL), and it accounts 
for about 2% of all NHLs [1]. The majority of acute lympho-
blastic leukemias (ALLs) are of the immature B-cell pheno-
type, whereas approximately 90% of LBL are of the immature 
T-cell phenotype [2, 3].
The natural history of B-LBL has not been well defined, 
and molecular studies are lacking because the literature is 
limited to small series and case reports. However, it is known 
that B-LBL has a predilection for children. In 1 study, a 
review of previous literatures reporting B-LBL in 105 pa-
tients, 64% (63 of 98) of patients for whom the age at diagnosis 
was available were younger than 18 years [4]. In Korea, 
the incidence of B-LBL has been reported to be 11.6% (42 
of 360 cases) in children with NHL [5], and only 0.12% 
(1 of 802 cases) in adults with NHL [6]. Patients with B-LBL 
mostly present with extranodal involvement sparing the bone 
marrow [4, 7]. The most affected sites are skin (33%), lymph 
node (22%), bone (19%), and mediastinum (5%) [4]. 
Although skin is the most affected site, primary involvement 
of the skin is a rare manifestation of B-LBL because cutaneous 
B-LBL usually presents secondary to systemic nodal B-LBL 
[8, 9]. Here we report a 78-year-old man with a single cuta-
neous lesion of B-LBL at diagnosis.
CASE REPORT
In September 2009, a 78-year-old man visited the Seoul 
Veterans Hospital with a dark red-colored mass on the right 
upper quadrant, which he had had for several months. The 
mass was approximately 50×60 mm in size, non-tender, 
non-itching, and round, and had a smooth surface (Fig. 1A). 
There were no palpable enlarged lymph nodes or any other 
skin lesions in any region, including the neck, axilla, and 
groin. Results of a biopsy specimen suggested lymphoma. 
He was subsequently transferred to the Korea Cancer Center 
Hospital for a further work-up.
A complete blood count revealed normal values, as follows; 
white blood cell count, 6.78×10
9/L; platelet count, 243×10
9/L; 
and hemoglobin, 14.0 g/dL. Aspartate transaminase was 8 
U/L (normal range, 4-43 U/L), alanine transaminase, 15 U/L 
(normal range, 8-38 U/L); uric acid, 6.7 mg/dL (normal range, Korean J Hematol 2011;46:283-6.
284 Su-Yeon Cho, et al. 
Fig. 1. (A) At diagnosis, a 50×60
mm non-tender, non-itching, and 
dark red tumor with smooth sur-
face was present on the right up-
per abdominal quadrant. (B) After 
the 3
rd session of cyclophospha-
mide, adriamycin, vincristine, and 
prednisolone (CHOP) chemothe-
rapy, the tumor disappeared by 
gross examination. (C) 
18F-fluo-
rodeoxyglucose (FDG) positron 
emission tomography (PET)/com-
puted tomography (CT) scan shows
a single hypermetabolic lesion 
(arrow) in the abdominal wall 
(standardized uptake value [SUV]= 
12.8).
3.4-7.0 mg/dL); lactate dehydrogenase, 286 U/L (normal 
range, 240-480 U/L); and alkaline phosphatase, 57 U/L 
(normal range, 40-129 U/L). Computed tomography (CT) 
of the chest showed normal findings. However, abdominal 
and pelvic CT scans depicted a 4-cm sized, discoid, highly 
attenuating mass in the skin of the right upper aspect of 
the abdomen without demonstrably enlarged lymph nodes. 
Gastroduodenofiberscopy and colonoscopy produced normal 
findings. 
18F-fluorodeoxyglucose (FDG) positron emission to-
mography (PET)/CT visualized a single hypermetabolic le-
sion in the abdominal wall (standardized uptake value 
[SUV]=12.8) (Fig. 1C).
A microscopic examination of the biopsied specimen re-
vealed small malignant cells with fine chromatin, convoluted 
nuclear membranes, and scant cytoplasm infiltrating the der-
mis (Fig. 2A, B). On immunohistochemical (IHC) staining, 
atypical cells showed positivity for B-cell lineage markers 
(CD79a, paired box 5 [PAX5], and precursor lymphoblastic 
marker (terminal deoxynucleotidyl transferase [TdT]) (Fig. 
2C-F). Staining for CD20 and CD3 was negative. Molecular 
studies for immunoglobulin heavy chain gene rearrangement 
also revealed B-cell monoclonality. The final pathological 
diagnosis was precursor B-LBL.
For staging, bilateral bone marrow (BM) and diagnostic 
spinal tapping (for cerebrospinal fluid [CSF] cytology) were 
performed. There was no evidence of lymphoma involve-
ment  in BM or C SF. O n th e basis o f t he path olo gical diagno sis 
and clinical staging, he was diagnosed as having primary 
cutaneous precursor B-LBL, Ann Arbor stage IEA (only lo-
calized, single extranodal site involvement). He was treated 
using the cyclophosphamide, adriamycin, vincristine, and 
prednisolone (CHOP) regimen (cyclophosphamide, 750 
mg/m
2; adriamycin, 35 mg/m
2; vincristine, 1.4 mg/m
2 
[maximum 2 mg] i.v. on day 1; and prednisolone, 100 mg 
p.o. on days 1-5), which is not an intensive multi-agent 
chemotherapy, because of his advanced age. For the same 
reason, the dose of adriamycin in the standard CHOP regimen 
was reduced from 50 mg/m
2 to 35 mg/m
2. After the 1st 
CHOP cycle, the mass shrank and had a flattened surface, 
and after the 3
rd cycle, the tumor disappeared by gross exami-
nation (Fig. 1B). Furthermore, 
18F-FDG PET/CT failed to 
depict a hypermetabolic lesion in the abdomen. We con-
cluded that he had achieved complete response (CR) after 
3 cycles of CHOP therapy. An additional CHOP cycle was 
then administered and the initial skin lesion site was sub-
jected to 3,600 cGy of radiotherapy over 4 weeks. At 21 
months after completing 4 cycles of CHOP treatment and 
radiotherapy, the patient was found to have maintained a 
state of CR.
DISCUSSION
Primary cutaneous B-LBL involving only the skin without 
systemic disease appears to occur almost exclusively in chil-
dren or young adults, and is extremely rare in older patients 
[7, 10]. Furthermore, it appears to be predominantly located 
in the head and neck region [9, 10]. Thus, the present case 
report of a single cutaneous lesion of B-LBL in the abdominal 
wall in a 78-year-old patient expands our knowledge of this 
disease.
For a differential diagnosis, comprehensive IHC staining Korean J Hematol 2011;46:283-6.
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Fig. 2. (A) Microscopically, skin biopsy specimen revealed diffuse infiltration of small to intermediate lymphoid cells in the dermis and subcutaneous
fat (hematoxylin & eosin [H&E], original magnification ×200). (B) High magnification shows monotonous tumor cells with slightly convoluted nuclei
with fine chromatin and occasionally nucleolus and scant cytoplasm (H&E, original magnification ×1,000). (C-F) Photographs of 
immunohistochemical staining. Most tumor cells are positive for leukocyte common antigen (LCA) (C), CD79a (D), paired box 5 (PAX5) (E), and 
terminal deoxynucleotidyl transferase (TdT) (F).
is crucial, but no single diagnostic immunohistologic pattern 
has been established for B-LBL. Nevertheless, certain im-
munophenotypic patterns can help distinguish malignant 
lymphomas and benign lymphoid proliferations. The 
work-up for the differential diagnosis of B-LBL includes 
small, blue, round cell tumors, e.g., Ewing’s sarcoma, 
Merkel’s cell carcinoma, neuroblastoma, rhabdomyosarco-
ma, Wilm’s tumor, neuroendocrine carcinoma, and meta-
static small cell carcinoma, as well as other lymphoid malig-
nant neoplasms [8]. B-lymphoblasts are positive for CD10, Korean J Hematol 2011;46:283-6.
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surface CD22, CD24, PAX5, and TdT in most cases, while 
the expression of CD20 and CD34 is variable [11]. In tissue 
sections, CD79a and PAX5 are most frequently used to dem-
onstrate B-cell differentiation, but the former reacts with 
some cases of T-ALL and, thus, is not specific [12]. In the 
present case, small malignant cells were positive for LCA, 
TdT, CD79a, PAX5, and bcl-2, but negative for CD20, CD10, 
and CD3. These immunohistochemical findings were con-
sistent with precursor B-LBL, although the cells were neg-
ative for CD20 and CD10.
Patients with B-LBL respond well to intensive multi-agent 
chemotherapy (ALL-type regimens or intensive NHL-type 
regimens) [4, 13]. According to some reports, adult patients 
with B-LBL seem to have better CR rates and longer response 
duration than those with acute B-LBL treated with similar 
regimens [7]. In addition, it has been suggested that survival 
is better for B-LBL than T-LBL [13]. Primary cutaneous 
and extracutaneous B-LBL are not different in the manage-
ments; both conditions should be treated with intensive che-
motherapy regardless of the staging results [4, 7, 13]. 
However, our case was treated using the CHOP regimen 
because of his far advanced age. Morel et al. reported treat-
ment outcomes by different treatment protocols in 80 adult 
patients with LBL. In that study, the CR rate with CHOP 
was 71% compared to 83% with the intensive NHL protocol 
(LNH-84) and 86-91% with 2 different ALL protocols (LALA 
or FRALLE) [14]. However, there was no significant differ-
ence in CR rate and CR duration among the regimens. In 
addition, there was no significant difference between the 
C H O P  a n d  L N H - 8 4  p r o t o c o l s  i n  o v e r a l l  s u r v i v a l  o f  A n n  
Arbor stage I to III patients (2-year survival, 62% and 74%, 
respectively; P=0.49). On the basis of the results demon-
strated by Morel et al., we suggest that the CHOP regimen 
can be a reasonable second option in elderly patient who 
would not tolerate standard intensive regimens for LBL.
The prognosis of patients with cutaneous LBL appears 
to be similar to that of patients with extracutaneous LBL 
[15]. Some authors have reported that a proportion of patients 
without systemic disease at diagnosis might progress to ad-
vanced disease with systemic involvement, most commonly 
to precursor B-ALL over a period of days to months [9]. 
These reports suggest that primary cutaneous precursor 
B-LBL has the potential to progress without adequate sys-
temic chemotherapy, and thus, cutaneous infiltrates might 
be an early manifestation of precursor B-LBL/lymphoma pro-
gression to diffuse disease [9].
In conclusion, we report a case of B-LBL presenting with 
a single cutaneous lesion without systemic involvement in 
an old man. This case suggests that the possibility of primary 
cutaneous B-LBL among several subtypes of cutaneous lym-
phomas be considered despite its rarity, when an adult patient 
presents with only skin involvement and has pathological 
findings compatible with lymphoma.
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